Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence Authors: Salvatore Perrone, Matteo Molica, Diana Giannarelli, Giada Pacitto, Simone Ferrero Published: 2026 ABSTRACT Pola-R-CHP regimen is the new standard of care for untreated diffuse large B-cell lymphoma (DLBCL) patients, following the POLARIX trial. This study evaluates whether clinical trial (RCT) efficacy and safety are reproducible in real-world evidence (RWE) settings. This systematic review and meta-analysis compared outcomes between RCTs and RWE studies. Primary endpoints were complete response (CR) rate, progression-free survival (PFS), and overall survival (OS). Meta-regression explored heterogeneity using age, International Prognostic Index (IPI), and activated B-cell-like (ABC) subtype as moderators. Data from 2 RCTs and 10 RWE studies (3472 patients) were integrated. The pooled CR rate was 78% (95% CI: 74–82%), with RWE studies showing a significantly higher CR (80%) than RCTs (69%, P < 0.001). The pooled 1-year PFS was 85%, significantly higher in RWE (86%) than RCTs (81%, P = 0.02). Pooled 1-year OS was 91%, with no significant difference between RWE (90%) and RCTs (94%, P = 0.35). Despite high heterogeneity (I2 74–91%), meta-regression confirmed that age, IPI score, and ABC subtype did not significantly influence treatment effects, though trends for improved CR and PFS were noted. In conclusion, this meta-analysis confirms that Pola-R-CHP outcomes in real-world practice are consistent with, and occasionally exceed, those observed in clinical trials. Despite inherent heterogeneity in RWE, these findings support Pola-R-CHP as a robust frontline therapy for a broad DLBCL population, regardless of baseline clinical characteristics. Introduction Diffuse large B-cell lymphomas (DLBCL) represent the most frequent histology of aggressive non-Hodgkin lymphoma (NHL) [1]. Its incidence increases with age, and the median age at diagnosis is 67 years, as reported by the SEER database [2]. For decades, the frontline therapy has been represented by R-CHOP, a chemoimmunotherapy regimen comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [3]. However, the POLARIX trial changed this scenario with the experimental combination able to achieve a statistically significant increase in PFS (6% gained at 2 years, p not statistically significant at the nominal 0.05 level) thanks to the introduction of polatuzumab vedotin in place of vincristine (Pola-R-CHP), but not OS benefit even at 5-years of follow-up [4, 5]. Pola-R-CHP is recommended for patients with an IPI ≥ 2, by ESMO and NCCN Guidelines [6, 7]. Moreover, the NCCN-B-Cell lymphoma ver 3.2026 also extends recommendation to limited stages with a smIPI >1 [7, 8]. Polatuzumab is an antibody-drug conjugate comprising a monoclonal antibody anti-CD79b, a component of the B cell receptor complex, linked to a payload of monomethyl auristatin-E (MMAE), a microtubule-disrupting agent [9]. In 2019, polatuzumab was also approved in second-line therapy (Polatuzumab vedotin plus bendamustine and rituximab) for r/r DLBCL [10]. and meta-analyses have already been performed in this setting [11]. On the contrary, Pola-R-CHP has been available since 2023 [12]. So these results in clinical practice have just begin to accumulate. Therefore, our objective was to use a systematic review and subsequent meta-analysis to evaluate the safety and effectiveness of Pola-R-CHP in patients with untreated DLBCL, mainly comparing results from randomized clinical trials (RCT) and the recent Real-world evidence studies (RWE). Methods This study was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [13]. Searches to identify studies that addressed Pola-R-CHP treatment were considered. It was recorded in PROSPERO: Id 1284137. Searches were run in January 2026, in the following databases: Ovid MEDLINE (All: 1946 to Present); The Cochrane Library (Wiley). Search strategy included all appropriate controlled vocabulary and keywords for the concepts of “Pola-R-CHP”, “polatuzumab”, “Polatuzumab vedotin”, and “lymphoma”. To limit publication bias, there were no language or publication date restrictions on the search strategy. We also included abstracts from ASH Congress 2025. To be eligible, studies had to meet the following inclusion criteria: (1) Enrolled patients diagnosed with DLBCL or LBCL receiving first-line treatment. (2) Randomized controlled trials (RCTs), regardless of blinding status and RWE. (3) Abstracts that provided sufficient details on study design, patient characteristics, interventions, and outcomes. Studies were excluded if they: (1) Did not report relevant outcomes. Had an unclear methodology. (2) Employed polatuzumab in 2nd or further lines. (3) Used reduced doses or different backbones of R-CHP. Two independent reviewers (SP and MM) assessed the literature based on predefined criteria We agreed to exclude studies with significant dose reductions in the treatment regimen (e.g., Pola-R-miniCHP, mini Pola-R-CHP [14, 15]. A Japanese RWE study was excluded from our analysis, because it focused on very elderly patients (>80 years), and a significant dose reduction to Pola-R-CHP was performed with initial dose attenuation and subsequent dose adjustments [16]. Primary endpoints were complete response (CR%); 1-year overall survival (OS); 1-year progression-free survival (PFS), and the incidences of febrile neutropenia, and incidence of peripheral neuropathy of any grade. The following data were extracted: (1) Study details (first author, year, median follow-up); (2) Patient characteristics (sample size, median age, IPI, COO status); (3) Outcomes (CRR,1-year and 2-year PFS, 1-year OS); (4) Adverse Events: (incidence of febrile neutropenia and peripheral neuropathy). Given anticipated clinical and methodological heterogeneity, random-effects models were applied for meta-analysis, with heterogeneity quantified using Q statistics and the I² index (DerSimonian and Laird [17]. Comparisons between RCT and RWE results were descriptive, based on subgroup-specific pooled estimates with corresponding confidence intervals. Forest plots and bubble plots were generated with JASP ver. 0.95.4 [18]. Results We found 60 records in Cochrane database, 50 records in PubMed, and 10 in ASH 2025, abstracts’ section. The PRISMA flow chart is shown in Supplementary Fig. 1. A total of 12 studies were included in the current meta-analysis, with a total of 2 RCTs and 10 RWE studies, comprising 3472 total patients. The pivotal POLARIX study randomized patients with newly diagnosed DLBCL between the standard R-CHOP and Pola-R-CHP. Moreover, in order to support a regulatory submission in China, an asian subpopulation analysis of the POLARIX study was performed: this subpopulation included patients enrolled from Asia during the global study phase, and a China extension cohort [19], with consistent results with the original trial. The second RCT randomized DLBCL patients between Mosunetuzumab-Pola-CHP vs. Pola-R-CHP (that was considered the standard arm) in a Phase II study [20]. All the other RWE studies were published in the last 2 years (between 2024 and 2025) mainly from China, Japan, Russia, and the USA [21–31]. This yielded different durations in the median follow-up between studies, with RCTs that had a weighted mean of 46.7 months, longer than the 10.4 months of the RWE studies. Indeed, the 2-year PFS is available only for RCT, but this data was not mature in the RWE studies and not reported in published papers. Study and patients’ characteristics are briefly summarized in Table 1.Table 1Summary of the study characteristics included into meta-analysis.StudyAuthor (year)Study typeN ptsMedian ageIPI 2%IPI 3–5%DHL %ABC %Median follow-up (months)1-year PF2-year PFS1-year OSCR %Febrile neutropenia %Peripheral neuropathy %POLARIX [4].Tilly H [4]RCT4406538625.93128.28176.788.77813.852.9POLARIX + Chinese extension [5].Morschhauser F [5]RCT5006538625.234.764.180.871.491.2Mosu-Pola-CHP vs. Pola-R-CHP [20].Westin J [20]RCT22633663028.681.881.8100779.118.2Beijing, China [22].Wang Z [22]RWE3663.963.913869772.22.8/Japan [23].Terao T [23]RWE356742169.9NA4711.986.792.875.7NA/Memorial Sloan Kettering [24].Iyengar V [24]RWE11466635911.381China, 6 Centers [25].Zhao P [25]RWE131693052.712.890.396.486.815.3Medicare [26].Matasar M [26]RWE1064759.388a86USA, 17 centers [27, 28].Thiruvengadam S [27]RWE53567633.934118191801537US community [29].Reagan P [29]RWE216706574010838715 USA, cancer centers [30]Scheffer Cliff E [30]RWE30567805529767677China: lower IPI or comorbidities [21].Ren Y [21]RWE1175620.5596.864.11090.591.376.57.717.1Russia [31].Tumyan G [31]RWE76638557.816.891898519.73.9Note that the first and second row represent the same study. In the second row POLARIX comprises the Chinese extension cohort and an extended follow-up at 5 years.RCT randomized clinical trial, RWE real world evidence, IPI international prognostic index, DHL double-hit lymphoma, ABC activated B-cell-like, PFS progression-free survival, OS overall survival, CR complete response.aTime to next treatment or death (TTNT-D), as a proxy for PFS. Table 1Summary of the study characteristics included into meta-analysis.StudyAuthor (year)Study typeN ptsMedian ageIPI 2%IPI 3–5%DHL %ABC %Median follow-up (months)1-year PF2-year PFS1-year OSCR %Febrile neutropenia %Peripheral neuropathy %POLARIX [4].Tilly H [4]RCT4406538625.93128.28176.788.77813.852.9POLARIX + Chinese extension [5].Morschhauser F [5]RCT5006538625.234.764.180.871.491.2Mosu-Pola-CHP vs. Pola-R-CHP [20].Westin J [20]RCT22633663028.681.881.8100779.118.2Beijing, China [22].Wang Z [22]RWE3663.963.913869772.22.8/Japan [23].Terao T [23]RWE356742169.9NA4711.986.792.875.7NA/Memorial Sloan Kettering [24].Iyengar V [24]RWE11466635911.381China, 6 Centers [25].Zhao P [25]RWE131693052.712.890.396.486.815.3Medicare [26].Matasar M [26]RWE1064759.388a86USA, 17 centers [27, 28].Thiruvengadam S [27]RWE53567633.934118191801537US community [29].Reagan P [29]RWE216706574010838715 USA, cancer centers [30]Scheffer Cliff E [30]RWE30567805529767677China: lower IPI or comorbidities [21].Ren Y [21]RWE1175620.5596.864.11090.591.376.57.717.1Russia [31].Tumyan G [31]RWE76638557.816.891898519.73.9Note that the first and second row represent the same study. In the second row POLARIX comprises the Chinese extension cohort and an extended follow-up at 5 years.RCT randomized clinical trial, RWE real world evidence, IPI international prognostic index, DHL double-hit lymphoma, ABC activated B-cell-like, PFS progression-free survival, OS overall survival, CR complete response.aTime to next treatment or death (TTNT-D), as a proxy for PFS. Summary of the study characteristics included into meta-analysis. Note that the first and second row represent the same study. In the second row POLARIX comprises the Chinese extension cohort and an extended follow-up at 5 years. RCT randomized clinical trial, RWE real world evidence, IPI international prognostic index, DHL double-hit lymphoma, ABC activated B-cell-like, PFS progression-free survival, OS overall survival, CR complete response. aTime to next treatment or death (TTNT-D), as a proxy for PFS. The pooled CR rate across all 10 studies where it was available (2132 patients) was 78% (95% confidence interval [CI]: 74-82%) with significant heterogeneity (Q = 37.84; P < 0.001; I² = 74%). Notably, pooled CR rates were significantly lower in RCT, 69% (95% CI: 45-93%) than in the RWE studies, i.e. 80% (95% CI: 76–83%), (P < 0.001) (Fig. 1A). The pooled results of eleven studies (not reported by Iyengar V. [24]) for a total of 3358 patients, showed that the 1-year PFS was 85% (95% confidence interval [CI]: 82–88%) with significant heterogeneity (Q = 46; P < 0.001; I² = 81%). Notably, pooled PFS were significantly lower in RCT 81% (95% CI: 78–83%) than in the RWE 86% (95% CI: 82–90%), (P = 0.02) (Fig. 1B). The pooled 1-year OS (reported by 11 studies, overall, 3358 patients) was 91% (95% confidence interval [CI]: 87–95%) with significant heterogeneity between studies (Q = 81; P < 0.001; I² = 91%). Notably, pooled OS were similar in RCT 94% (95% CI: 52–100%) and RWE 90% (95% CI: 85–96%) (P = 0.29) (Fig. 1C).Fig. 1Forest-plots of clinical end-points associated with efficacy of Pola-R-CHP. A Forest plot of the reported rate of Complete Response (CR). In Red are depicted RCT, in green RWE. B Forest plot of the reported rate of Progression-Free survival (PFS). In Red are depicted RCT, in green RWE. C Forest plot of the reported rate of the 1-year Overall survival (OS). In Red are depicted RCT, in green RWE. Forest-plots of clinical end-points associated with efficacy of Pola-R-CHP. A Forest plot of the reported rate of Complete Response (CR). In Red are depicted RCT, in green RWE. B Forest plot of the reported rate of Progression-Free survival (PFS). In Red are depicted RCT, in green RWE. C Forest plot of the reported rate of the 1-year Overall survival (OS). In Red are depicted RCT, in green RWE. To assess the signals of safety of the Pola-R-CHP, we focused on the reported adverse events (AEs) of febrile neutropenia and peripheral neuropathy that represent two peculiar toxicities of monomethyl auristatin E (MMAE) [32, 33]. These AEs are obviously well documented in the prospective RCTs, but only 4 RWE reported them. For febrile neutropenia we found an overall incidence of 11% (95% CI: 4–16%) (Fig. 2A). Incidence of febrile neutropenia was 12% vs. 9% in RCTs and RWE, respectively (p = 0.37). In the dataset there was heterogeneity with Q = 18, p = 0.001, and I2 = 80%. Peripheral neuropathy of any grade was overall reported in 27% (95% CI: 10–45%) of patients, in the RCTs incidence was 33% vs. 23% for RWE (Fig. 2B) p = 0.52. Heterogeneity was present between studies (Q = 96, I2 = 95%; p < 0.001).Fig. 2Forest-plot of the main Adverse events (AEs) for Pola-R-CHP. A Incidence of Febrile neutropenia. Forest-plot. B Incidence of Peripheral Neuropathy: Forest plot. Forest-plot of the main Adverse events (AEs) for Pola-R-CHP. A Incidence of Febrile neutropenia. Forest-plot. B Incidence of Peripheral Neuropathy: Forest plot. We then proceeded to perform a meta-regression of factors that could explain the heterogeneity between the different studies. The median age was considered as a continuous moderator. The analysis aimed to determine whether the median age of the participants (ranging from 56 to 75 years) influenced the observed effect size. The results of the meta-regression indicated that age is not a significant moderator of the treatment effect. The regression slope was nearly null (P = 0.9), suggesting that the effect size on PFS and OS remains stable regardless of the participants’ age. As shown in the Bubble Plot (Fig. 3), the regression line is essentially horizontal, and the individual studies are distributed uniformly along the age axis without showing a clear upward or downward trend.Fig. 3Bubble-Plot of meta-regression of median age of the studies, on OS (top) and PFS (bottom). Bubble-Plot of meta-regression of median age of the studies, on OS (top) and PFS (bottom). Moreover, we analyzed the effect of the representation in each study of a higher frequency of patients with higher IPI, that is, a known negative prognostic factor in patients with DLBCL treated with R-CHOP [34]. The results of the meta-regression for IPI showed a downward trend that was progressively more pronounced, from OS, PFS, and CR. Only in the bubble-plot of CR the moderator reached a P = 0.06, at limit of statistical significance (Fig. 4).Fig. 4Bubble-Plot of meta-regression of patients with higher IPI on OS (top) and PFS (bottom). Bubble-Plot of meta-regression of patients with higher IPI on OS (top) and PFS (bottom). Next, we analyzed two biological factors, the rate of patients with Double-Hit lymphomas (DHL) and the percentage of patients with a cell-of-origin of Activated B-cell-like (ABC), that are classically associated with poor outcomes in patients treated with R-CHOP [1, 35, 36]. Only 5 studies reported the prevalence of patients with DHL, and this low percentage ranged from 7 to 3.8% (See Table 1). The results of the meta-regression showed that DHL% did not show a clear upward or downward trend for OS, PFS, and CR (Supplementary Fig. 2). The last moderator we analyzed was the percentage of patients harboring an ABC phenotype, that was reported by all studies, except [26], with a range from 31% in the POLARIX study to 64% reported by Ren et al. [4, 21]. It should be noted that different techniques were used to determine the cell of origin (COO) subtype, for example, the POLARIX used gene expression profiling, while the Hans classifier by immunohistochemistry [37], was widely used in RWE studies like the study reported by Scheffer Cliff et al., which specifically focused on this subject [30]. The results of the meta-regression showed that ABC% had an upward effect on PFS (P = 0.18) and CR rate (P = 0.56) curves, while it had only minimal downward effect on OS (p = 0.6) (Fig. 5).Fig. 5Bubble-Plot of meta-regression of the percentage of ABC patients included with effects on CR (top) PFS (middle), and OS (bottom). Bubble-Plot of meta-regression of the percentage of ABC patients included with effects on CR (top) PFS (middle), and OS (bottom). Considering the high heterogeneity registered, we tried to conduct a sensitivity analysis by excluding the largest MEDICARE study [26]. and the smallest RCT [20]. In both cases, I [2] decreased but always >70%. Discussion In this systematic review and meta-analysis on Pola-R-CHP we analyzed the frontline therapy of DLBCL, making a comparison of the main clinically significant outcomes emerging from randomized to real-world studies. RCTs and RWE capture different data, for example, RCTs capture with more homogeneity AEs and response criteria (e.g., Lugano criteria [38]. are applied more stringently than in clinical practice. On the other hand, RWE generally includes patients with more comorbidities, and DLBCL can be more unfavorable than the stringent inclusion/exclusion criteria employed in the screening procedures of RCTs. Briefly, we found that the pooled 1-year PFS was 85%, significantly higher in RWE (86%) than RCTs (81%, P = 0.02) while the pooled 1-year OS was 91%, with no significant difference between RWE (90%) and RCTs (94%, P = 0.35). These findings corroborate the real-world use of polatuzumab, as recommended by ESMO and NCCN guidelines [6, 7]. DLBCL is a curable disease, many efforts have been done from the introduction of rituximab to improve the back-bone of CHOP chemotherapy in the last 2 decades [39]. The strategy of adding a new drug X to R-CHOP failed with several candidates (e.g., bortezomib, lenalidomide, ibrutinib) [40–43]. This changed with the exception of Pola-R-CHP that improved PFS in comparison to R-CHOP [5, 44]. However, these results might appear of limited clinical impact, with a 5-year ΔPFS of only 5.8% [5], and no impact on OS over the standard R-CHOP. Therefore, Pola-R-CHP is considered cost-effective according to some authors [45]. Though showing only a 56.6% chance of being cost-effective, dependent both on the sustained PFS benefit of Pola-R-CHP over R-CHOP with longer follow-up, and on the high price of a potentially avoidable CAR T-cell therapy as second-line treatment in case of progression/early relapse [46]. Conversely, an alternative Chinese pharmaco-economical study arrived to the opposite conclusion that Pola-R-CHP is not cost-effective with the actual published prices [47]. Therefore, a still unmet critical issue is the comparison of the results of Pola-R-CHP in the pivotal RCT to those of RWE studies. The two RCTs presented are different, since POLARIX was a pivotal phase III study that led to the approval of Polatuzumab in the first line [4]. Indeed, the second RCT was a phase II where the experimental arm was the mosu-pola-CHP combination and Pola-R-CHP was considered the standard arm [20]. Therefore, the latter was focused on the typical side effects of bispecific CD20xCD3 drugs like CRS and ICANs. However, a further comparison of the adjunct of mosu on a backbone of pola-R-CHP was outside the objectives of this current meta-analysis. Our systematic review and meta-analysis provide interesting results about the published evidence on the use of Polatuzumab front-line. We noticed that the pooled results of patients considered in the RWE compare favorably than those enrolled in the two RCT, especially in terms of complete responses and percentage of patients’ progression-free at 1 year from the start of Pola-R-CHP. However, our pooled results should be interpreted cautiously, since they could overestimate benefit in RWE due to shorter follow-up, possible patients’ selection and survivor bias. In general, we should also acknowledge that the definition of CR is more stringent in RCTs, due to radiologic and PET centralization, as well as accurate application of Lugano response criteria, possibly downgrading what is evaluated from investigator-reported response. Another possible explanation could be a better selection in clinical practice of those patients that could benefit more of the addition of Polatuzumab. For example, in 15 American Cancer centers, patients with ABC subtype [48]. seemed to benefit more from polatuzumab exposure. In the POLARIX trial, patients with ABC DLBCL had a hazard ratio of 0.34 for disease progression, relapse, or death compared to 1.18 in GCB DLBCL, indicating a substantial benefit in the former group [44]. Possible biological explanations are the peculiar sensitivity of ABC to Polatuzumab by microtubule disruption by MMAE, as well as BCR signaling abrogation via CD79b internalization, triggered by antibody-drug conjugate binding [48]. Indeed, our meta-regression found a trend for the benefit of polatuzumab in studies that included more patients in the ABC subtype. Moreover, as the POLARIX study showed that patients with higher IPI and bulky masses benefit more from polatuzumab [4, 5]. These patients might have received preferentially Pola-R-CHP in RWE, thus augmenting the apparent benefit in these studies. On the other hand, it is not surprising that no OS difference was described between RCT and RWE. This could be explained by the limited median FU in the more recent RWE studies, and the increased salvage possibilities with second lines based on CAR T-cells [49, 50], and other drugs for patients ineligible to CAR-T [51, 52]. The two adverse events more relevant to the introduction of polatuzumab: peripheral neuropathy (23%) and febrile neutropenia (11%), resemble similar incidence between RCTs and RWEs. However, there could be the effect of an under-reporting of AEs in RWEs than in RCTs. Our study has several limitations. We found high variability and heterogeneity between studies (I2 = 80% for PFS and I2 = 91% for OS), and our predictors (age, IPI, DHL%) failed to explain the reasons of this heterogeneity. Probably, the observed differences are secondary to other factors we did not include, like the enrollment of patients from very different worldwide countries: China [21, 22, 25], Japan [23], USA [24, 26, 27, 29, 30], Russia [31]. Differences in local practice and differences in the modality of assessment of clinical response and severity of AEs. Most importantly, one RWE was a registry-study extrapolated from MEDICARE, which represented the most relevant group with 1065 patients [26]. In this study, patients were older (median 75 years) and only PFS and OS at 1 year were reported, probably for the impossibility of extrapolating direct clinical information such as CR rate and IPI or COO histologic subtype. Also, excluding this study, heterogeneity remained high. Comparing COO results was difficult because clinical trials used gene expression profiling (GEP), while real-world data mostly used the Hans classifier. Our meta-analysis was unable to account for these different methodologies separately. So, results regarding COO should be interpreted with caution. In conclusion, data from our large meta-analysis pooling about 3500 patients show that Pola-R-CHP is effective in clinical practice at least, if not better, than results obtained in the RCT. Also, the signals of toxicity regarding peripheral neuropathy and febrile neutropenia are similar in the two kinds of studies. Actually, at least 15 trials are ongoing to test different frontline approaches in LBCL [39], also including tafasitamab plus lenalidomide and R-CHOP [53]. This will probably change available therapeutic options for DLBCL; meanwhile, this meta-analysis sheds light into the clinical practice of targeting CD79B with Pola-R-CHP. Supplementary information Supplemental material for review Reproducibility checklist Supplemental material for review Reproducibility checklist